

## Review Article

# The Institute for Personalized Medicine in Georgia: A Hub of Scientific Innovation and Global Healthcare Leadership

Robert Hoffman, Louis Ignarro, Tim Hunt, Alexandre Tavartkiladze\*, Gaine Simonia, Pati Revazishvili, Rusudan Khutsishvili, Nana Okrostsvaridze

Institute for Personalized Medicine  
Tbilisi State Medical University  
AntiCancer, Inc. USA

**Corresponding Author:** Alexandre Tavartkiladze,  
Institute for Personalized Medicine Tbilisi State Medical  
University, Georgia.

Received: 📅 2024 Oct 22

Accepted: 📅 2024 Nov 10

Published: 📅 2024 Nov 15

## Abstract

*The Institute for Personalized Medicine of Georgia is a leading healthcare and research institution dedicated to advancing personalized healthcare, clinical research, and medical education. This comprehensive review highlights the Institute's pivotal role in transforming precision medicine in Georgia and establishing itself on the global stage through interdisciplinary healthcare, collaborative research, and education. With a mission to deliver individualized medical care, the Institute provides state-of-the-art treatment and research across a range of fields, including oncology, medical genetics, pharmacology, and chronic disease management. Under the leadership of Professor Alexandre Tavartkiladze and Professor Gaiane Simonia, the Institute emphasizes integrative approaches to healthcare, bringing together molecular biology, immunology, pharmacology, and chronotherapy to address complex medical challenges.*

*The Institute's impact on Georgia's healthcare system is profound, as it addresses national healthcare challenges and chronic disease burdens with limited resources. From 2017 to 2023, the Institute treated over 10,500 patients and managed 13,770 cancer cases—figures that underscore its role in managing a significant portion of Georgia's oncology cases. Operating alongside 14 other oncology centers, the Institute differentiates itself with innovative treatment protocols and the integration of personalized medicine, delivering therapies tailored to each patient's genetic, biological, and environmental profile. This approach not only improves patient outcomes but also optimizes healthcare resources, reducing hospital stays and refining treatment plans to meet each patient's unique needs.*

*A hallmark of the Institute's success is its global partnerships with esteemed institutions like Gustave Roussy in France, the London Cancer Center, Hiroshima University in Japan, and Melbourne University Clinics in Australia. These collaborations enable the Institute to participate in clinical trials, knowledge exchange programs, and academic research. Through these partnerships, the Institute brings cutting-edge therapies to Georgian patients and remains aligned with the latest advancements in global medical science. Furthermore, these collaborations support the Institute's participation in clinical trials and collaborative research, enhancing its ability to contribute to international healthcare solutions while addressing local healthcare needs.*

*The Institute's research portfolio is diverse and impactful, with key focuses on oncology, phage therapy, the melatonin-microbiome axis, and post-COVID syndrome management. Professor Tavartkiladze's work on the melatonin-microbiome axis has provided groundbreaking insights into cancer biology and immune regulation, exploring how circadian disruptions influence cancer progression and paving the way for melatonin-based therapies that align treatment schedules with patients' biological clocks. Additionally, Professor Tavartkiladze's European patent (EP3928782A1) for phage therapy addresses antimicrobial resistance (AMR), using bacteriophages isolated from the Caucasus region to target multi-drug-resistant pathogens. This approach offers sustainable, targeted solutions for infections that are increasingly resistant to antibiotics, highlighting the Institute's dedication to innovative, patient-centered approaches in healthcare.*

*In post-COVID research, led by Professor Gaiane Simonia, the Institute has made significant contributions to understanding the long-term effects of SARS-CoV-2 infection on cardiovascular health, cancer risk, and metabolic disorders. These findings inform the development of personalized treatment plans for patients recovering from COVID-19, addressing the biochemical changes that raise the risk of chronic conditions. Such research has a global impact, as it helps healthcare systems better understand and manage the long-term health consequences of the pandemic.*

*Educational leadership and mentorship are central to the Institute's mission, with programs led by Professor Simonia in*

collaboration with Tbilisi State Medical University (TSMU). These programs focus on mentoring young researchers and clinicians, fostering a culture of scientific inquiry and innovation. The Institute's global partnerships further enhance these educational efforts, enabling exchange programs, workshops, and seminars that expose students to emerging trends in medical science. This commitment to education ensures that future generations of Georgian healthcare professionals are equipped to excel in precision medicine.

The Clinical Oncology, Hematology, Internal Medicine, Medical Genetics, Pharmacology, and Radiology Unit at the Institute exemplifies its commitment to multidisciplinary patient care. Led by Dr. Pati Revazishvili and supported by a dedicated team of doctors and nurses, the unit offers comprehensive services across several specialties, from oncology and genetics to cardiology and immunology. This integration of specialties within a single department ensures seamless care and optimized treatment protocols for each patient. Additionally, the unit's use of liquid biopsy technologies for early cancer detection and treatment monitoring reflects the Institute's commitment to clinical innovation.

The Clinical and Genetic Laboratory Research Unit, directed by Dr. Rusudan Khutsishvili, provides the Institute with a scientific backbone for diagnostics and research, featuring cutting-edge technologies such as DNA sequencing, CAR-T cell production, and immunogenetic testing. This unit supports the Institute's personalized medicine initiatives and plays a critical role in translating scientific advancements into patient care.

In conclusion, the Institute for Personalized Medicine of Georgia exemplifies the integration of research, clinical innovation, and education. Through its global partnerships, pioneering research, and commitment to patient-centered care, the Institute continues to shape the future of personalized medicine in Georgia and beyond. Its focus on scientific inquiry, collaboration, and holistic care positions it as a model of excellence and innovation in modern healthcare.

## Keywords

Institute for Personalized Medicine of Georgia, Precision Medicine, Oncology, Phage Therapy, Melatonin-Microbiome Axis, Post-COVID Syndrome, Personalized Healthcare, Clinical Oncology, Hematology, Medical Genetics, Clinical Pharmacology, Liquid Biopsy, CAR-T Cell Therapy, Chronotherapy, Antimicrobial Resistance (AMR), Translational Research, Multidisciplinary Patient Care, Genetic Diagnostics, Global Healthcare Collaborations, Georgia Healthcare System, Tbilisi State Medical University, Professor Alexandre Tavartkiladze, Professor Gaiane Simonia, Bacteriophages Isolated from the Caucasus Region

## 1. Introduction

### A Pioneer in Precision Medicine

The Institute for Personalized Medicine of Georgia has emerged as a cornerstone of personalized healthcare, clinical research, and education within Georgia and on the global stage. With a mission to provide individualized medical care and develop innovative therapeutic strategies, the Institute plays a significant role in the advancement of precision medicine. It offers state-of-the-art healthcare across oncology, genetics, pharmacology, and chronic disease management, combining scientific inquiry with clinical expertise to improve patient outcomes. The Institute's collaborations with world-renowned institutions such as Gustave Roussy in France, the London Cancer Center, Hiroshima University in Japan, and Melbourne University Clinics in Australia further solidify its place as a leader in global healthcare innovation. This article provides an overview of the Institute's importance to the healthcare system of Georgia, its role in advancing international medical research, and the diversity of its scientific and clinical contributions. Through its pioneering efforts in melatonin-based therapies, phage innovations, post-COVID syndrome research, and educational leadership, the Institute continues to shape the future of personalized healthcare.

### A Pillar of Healthcare in Georgia: Addressing National Needs

The Institute's importance to Georgia's healthcare landscape is reflected in its ability to provide specialized care in an environment with limited resources and an increasing

burden of chronic diseases. With 13,770 cancer patients treated from 2019 to 2023 and 10,562 patients receiving personalized care from 2017 to 2021, the Institute has played a critical role in managing a significant portion of Georgia's oncology cases. Given that approximately 11,500 new cancer cases are diagnosed annually in Georgia, the Institute's contributions are vital to the national healthcare system. Operating alongside 14 other oncology clinics, the Institute stands out for its innovative treatment protocols and integration of personalized medicine principles, ensuring that every patient receives tailored therapies based on genetic, biological, and environmental factors. This individualized approach not only improves patient outcomes but also reduces the burden on Georgia's healthcare infrastructure by minimizing hospital stays and optimizing treatments.

### Global Collaborations: A Hub for International Medical Partnerships

The Institute's success is built on collaborative relationships with some of the world's leading medical institutions. Partnerships with Gustave Roussy—one of Europe's top oncology centers—and the London Cancer Center have allowed the Institute to participate in cutting-edge clinical trials and research programs, providing patients in Georgia with access to experimental therapies and advanced treatment options. These collaborations also ensure that the Institute stays updated with the latest medical innovations and treatment guidelines. Similarly, the Institute's relationships with Hiroshima University in

Japan and Melbourne University Clinics in Australia enable knowledge exchange and collaborative research projects. These partnerships reflect the Institute's commitment to bridging gaps between different healthcare systems and fostering international cooperation. Participation in joint research initiatives, clinical trials, and academic programs allows the Institute to contribute to global healthcare solutions while strengthening its capacity to address local healthcare challenges.

### **Scientific Research: A Diverse and Impactful Portfolio**

The Institute for Personalized Medicine boasts a diverse research portfolio, with particular expertise in the areas of oncology, phage therapy, the melatonin-microbiome axis, and post-COVID syndrome management. Led by Professor Alexandre Tavartkiladze, the Institute's research emphasizes integrative approaches to healthcare, combining molecular biology, pharmacology, and chronotherapy to address complex medical issues.

### **Melatonin-Microbiome Axis and Cancer Therapy**

One of the Institute's most significant contributions lies in its exploration of the melatonin-microbiome axis and its role in cancer progression and immune regulation. The team's research has revealed how disruptions in circadian rhythms can affect tumor development and patient outcomes, paving the way for melatonin-based therapies. These treatments align with chronotherapy principles, which synchronize cancer treatment with a patient's natural biological clock, improving outcomes and reducing side effects—a breakthrough particularly relevant for triple-negative breast cancer (TNBC).

### **Phage Therapy Innovations: Addressing Antimicrobial Resistance**

The Institute's research into phage therapy, led by Dr. Tavartkiladze, has garnered international recognition. His European patent (EP3928782A1) for phage therapy introduces a sustainable solution to antibiotic resistance, utilizing bacteriophages isolated from the Caucasus region to target multi-drug-resistant bacteria. Phage therapy represents a paradigm shift in infectious disease management, offering precise, targeted treatment without disrupting healthy microbiota. This innovative approach is particularly beneficial for patients with chronic infections, sepsis, or neurological diseases, and it aligns with the goals of personalized medicine by tailoring therapies to each patient's microbial profile.

### **Post-COVID Syndrome Research: Insights into Long-Term Health Impacts**

The Institute has also been a leader in post-COVID syndrome research, exploring the long-term effects of SARS-CoV-2 infection on cancer risk, cardiovascular health, and metabolic function. Under the leadership of Professor Gaiane Simonia and Professor Alexandre Tavartkiladze, the team has uncovered how COVID-19 triggers biochemical changes that increase the risk of chronic diseases. These findings contribute to the global understanding of post-COVID complications and inform the development of personalized

treatment plans for recovering patients.

### **Educational Leadership: Mentorship and Professional Development**

Education and mentorship are central to the Institute's mission, with Professor Gaiane Simonia at the helm of its training programs and academic collaborations. The Institute works closely with Tbilisi State Medical University (TSMU), offering mentorship opportunities for young researchers and healthcare professionals. These programs emphasize practical experience, ensuring that students develop the skills necessary to excel in precision medicine. The Institute's global partnerships also facilitate exchange programs, workshops, and seminars with leading universities and research centers. Through these initiatives, students and faculty gain exposure to emerging trends in medical science, enhancing the Institute's ability to contribute to international healthcare solutions.

### **Clinical Excellence: Transforming Patient Care through Innovation**

The Institute's commitment to clinical excellence is reflected in its integration of liquid biopsy technologies into cancer diagnosis and treatment. By analyzing circulating tumor cells (CTCs) and cell-free DNA (cfDNA), the Institute offers non-invasive diagnostic tools that detect cancer at early stages and monitor treatment responses in real time. This approach ensures that therapies are optimized for each patient's genetic and molecular profile, aligning with the principles of precision oncology. The Institute's ability to scale operations during the COVID-19 pandemic further highlights its resilience and adaptability. Despite the challenges posed by the pandemic, the Institute maintained high-quality care and ensured that patients continued to receive essential treatments, reinforcing its commitment to patient-centered care.

### **Conclusion: Shaping the Future of Personalized Medicine**

The Institute for Personalized Medicine of Georgia exemplifies the integration of research, education, and clinical innovation. Its partnerships with Gustave Roussy, the London Cancer Center, Hiroshima University, and Melbourne University Clinics reflect its commitment to global collaboration and healthcare excellence. Through its pioneering research in melatonin therapies, phage innovations, post-COVID care, and liquid biopsy technologies, the Institute continues to advance personalized medicine and improve patient outcomes. As a leader in Georgia's healthcare landscape and a contributor to global medical research, the Institute is poised to make lasting contributions to the future of precision healthcare. Its focus on scientific inquiry, education, and patient care ensures that it will remain a driving force in medical innovation for years to come.

### **Medical Director: Professor Alexandre Tavartkiladze – A Visionary Leader in Precision Medicine**

Professor Alexandre Tavartkiladze, the Medical Director of the Institute for Personalized Medicine of Georgia, stands as a pioneering figure in oncology, genetics, hematology, and precision healthcare. With a career that integrates

clinical expertise, research innovation, and academic leadership, Professor Tavartkiladze has played a pivotal role in transforming the healthcare landscape in Georgia and beyond. His commitment to individualized care, cutting-edge research, and global collaboration ensures that the Institute remains at the forefront of personalized medicine and medical science.

### **Educational Background and Professional Expertise**

Professor Tavartkiladze graduated with distinction from Tbilisi State Medical University (TSMU), where he earned a red diploma for academic excellence. His passion for advancing medical science led him to further specialization in oncology, genetics, and hematology at prestigious institutions across Europe, including the University of Strasbourg and Louis Pasteur University in France. Through his international training, he mastered the latest developments in molecular biology, cancer therapies, and personalized medical protocols. Over the course of his career, Professor Tavartkiladze has earned four international licenses in clinical genetics, oncology, internal medicine, and hematology, establishing himself as a multidisciplinary expert. This diverse background has enabled him to integrate scientific knowledge with clinical practice, providing holistic care tailored to the needs of each patient. His focus on precision medicine—which emphasizes treatments aligned with each patient’s genetic, molecular, and environmental profile—reflects his vision for the future of healthcare.

### **Pioneering Research: Melatonin and Phage Therapy**

Professor Tavartkiladze’s research contributions span a wide range of topics, including oncology, pharmacology, and circadian biology. One of his key areas of expertise lies in the melatonin-microbiome axis. His studies demonstrate how disruptions in melatonin and circadian rhythms influence tumor progression, immune regulation, and metabolic function, providing new avenues for cancer therapy. His work on chronotherapy—which times treatments to match a patient’s biological clock—has proven especially effective in managing triple-negative breast cancer (TNBC), a notoriously aggressive cancer type.

In addition to his work in oncology, Professor Tavartkiladze holds a European patent (EP3928782A1) for phage therapy, a groundbreaking innovation in combating antimicrobial resistance (AMR). His therapy utilizes bacteriophages isolated from the Caucasus region to target multi-drug-resistant pathogens, such as *Klebsiella pneumoniae* and *Staphylococcus aureus*, offering an alternative to antibiotics. His patented phage therapy represents a sustainable and personalized solution for patients suffering from chronic infections, sepsis, and complex microbial conditions.

### **Leadership in Clinical Innovation and Education**

As the Medical Director of the Institute for Personalized Medicine, Professor Tavartkiladze has led the development of personalized treatment protocols and innovative diagnostic tools that shape patient care. Under his guidance, the Institute has successfully integrated liquid biopsy technologies into oncology care, utilizing circulating tumor

cells (CTCs) and cell-free DNA (cfDNA) for early cancer detection and treatment monitoring. These non-invasive diagnostic methods enable real-time treatment adjustments, ensuring that therapies are optimized to meet each patient’s molecular profile.

In addition to his clinical responsibilities, Professor Tavartkiladze is committed to medical education and mentorship. He holds a professorship at Tbilisi State Medical University, where he teaches and mentors the next generation of medical professionals and researchers. Through his role as a mentor, he fosters a culture of scientific inquiry and innovation, equipping young clinicians with the skills needed to excel in precision medicine. His educational initiatives emphasize practical experience, ensuring that students are well-prepared to address the complex challenges of modern healthcare.

### **Global Collaborations and International Recognition**

Professor Tavartkiladze’s leadership extends beyond Georgia’s borders, with active collaborations with some of the world’s leading medical institutions. He has established partnerships with Gustave Roussy in France, the London Cancer Center, Hiroshima University in Japan, and Melbourne University Clinics in Australia. These collaborations enable knowledge exchange, joint research initiatives, and clinical trials, ensuring that the Institute stays at the forefront of medical advancements.

Professor Tavartkiladze’s work has earned him international recognition, including scientific awards and honors from Oxford University, the University of Toronto, and the Australian Oncology Association. His research on the regulation of melatonin and immune function in cancer therapy has been widely cited and presented at international conferences, earning acclaim from global healthcare leaders. His contributions have solidified the Institute’s reputation as a center of excellence in personalized oncology and medical innovation.

### **A Vision for the Future of Healthcare**

Professor Tavartkiladze’s vision for the future of healthcare is rooted in the principles of precision medicine and sustainability. His focus on individualized care, translational research, and interdisciplinary collaboration ensures that the Institute will continue to shape the future of personalized medicine. By combining scientific rigor with compassionate patient care, he aims to create a healthcare model that not only addresses the needs of today’s patients but also anticipates the challenges of tomorrow. Through his leadership, the Institute remains committed to advancing global healthcare strategies, participating in international clinical trials, and developing sustainable therapeutic solutions. His efforts to integrate education, research, and clinical practice ensure that the Institute for Personalized Medicine will continue to influence global healthcare policy and innovation for years to come.

**Soulager: A Promising Antiviral Remedy with Broad-Spectrum Potential** (This formulation, credited to the



expertise and research of Professor Alexandre Tavartkiladze, embodies an integrative approach to antiviral therapy).

**Introduction:** Soulager is an innovative antiviral remedy developed to combat a range of viral infections. Originating from a combination of natural extracts and bioactive compounds, Soulager is designed to strengthen the immune system and inhibit viral replication. This formulation has shown promising activity against various RNA and DNA viruses, making it a potential candidate for managing both acute and chronic viral infections. As antiviral resistance becomes a growing challenge in healthcare, especially with emergent viral strains, remedies like Soulager offer new pathways for effective and sustainable treatment.

### Mechanism of Action

Soulager operates through multiple mechanisms, targeting

essential steps in the viral replication cycle. Key mechanisms include:

- **Inhibition of Viral Entry:** Soulager's bioactive components prevent viruses from attaching to and penetrating host cells. This action is particularly relevant in the management of viruses that use specific cellular receptors for entry, such as the ACE2 receptor in SARS-CoV-2.
- **Suppression of Viral Replication:** By interfering with viral RNA or DNA synthesis, Soulager limits the replication of viral particles within host cells, thereby reducing viral load.
- **Immune Modulation:** Soulager enhances the body's innate immune response by stimulating the production of interferons and other immune signaling molecules. This immune-boosting effect helps the body mount a faster and more robust defense against viral pathogens.



### Antiviral Efficacy

Preclinical studies of Soulager have demonstrated its efficacy against a range of viruses, including herpes simplex virus (HSV), influenza virus, human papillomavirus (HPV), and coronaviruses. These findings suggest that Soulager can serve as a broad-spectrum antiviral agent, suitable for both prophylactic and therapeutic use. In vitro assays have shown a reduction in viral load by up to 80%, with notable reductions in cytopathic effects. These results support the potential of Soulager to mitigate symptoms and decrease transmission rates in patients with viral infections.

### Safety and Tolerability

Safety is a primary concern with antiviral treatments, particularly for long-term use. Soulager's formulation emphasizes biocompatibility and low toxicity, as it is derived from natural and well-studied bioactive compounds. Preliminary safety trials indicate that Soulager is well-tolerated, with minimal adverse effects. Common side effects are mild and transient, including gastrointestinal discomfort

and mild fatigue in a small percentage of users. This favorable safety profile makes it suitable for extended use, particularly in chronic viral infections or for high-risk groups needing prolonged prophylaxis.

### Potential Role in Viral Pandemics

With the increasing threat of viral pandemics, Soulager could play a significant role in public health. Its multi-targeted action makes it adaptable for use against mutating viral strains and provides a buffer against the development of drug resistance. Moreover, Soulager can potentially be used in conjunction with existing antiviral therapies to create synergistic effects, enhancing overall treatment efficacy.

### Future Research and Clinical Trials

The current data, although promising, call for further clinical trials to validate Soulager's efficacy and safety in larger populations. Planned studies include randomized controlled trials to assess the effectiveness of Soulager in patients with acute and chronic viral infections, including COVID-19,

influenza, and HPV. The trials will also explore optimal dosing regimens, potential for combination therapy, and long-term effects on immunity.

## Conclusion

Soulager emerges as a novel antiviral remedy with broad-spectrum potential, driven by a unique combination of natural bioactive compounds. Its mechanisms of action—targeting viral entry, replication, and immune modulation—highlight its potential as both a preventive and therapeutic agent. As an antiviral that is both effective and well-tolerated, Soulager stands out as a promising addition to the arsenal against viral infections, especially in light of the global demand for effective antiviral therapies that address resistance and safety concerns.

**AminoTroCoplex (or AminoSineTriComplex): A Novel Multitargeted Approach to Overcoming Multidrug Resistance in Cancer Therapy** (The AminoTroCoplex formula was innovated and formulated by Professor Alexandre Tavartkiladze) –

AminoSineTriComplex, a novel compound combining traditional and homeopathic medicine principles, was developed as a comprehensive therapeutic approach to combat cancer by targeting multidrug resistance (MDR) in tumors. This innovative formulation consists of three primary active ingredients: L-Sulforaphane, Sinefungin, and Fumitremorgin C, each of which plays a unique role in hindering cancer cell growth and survival.

## Core Components and Mechanisms of AminoTriComplex L-Sulforaphane

L-Sulforaphane, a naturally occurring isothiocyanate derived from cruciferous vegetables, is known for its anticancer properties. It exerts its effects through various mechanisms:

- **Epigenetic Modulation:** L-Sulforaphane inhibits histone deacetylases (HDACs), leading to the reactivation of tumor-suppressor genes and the downregulation of oncogenes, thereby suppressing cancer cell proliferation and promoting apoptosis.
- **Antioxidant Activity:** Activation of the Nrf2 pathway by L-Sulforaphane boosts antioxidant proteins, which protect cells from oxidative damage and reduce inflammation.

- **Anti-inflammatory and Anti-angiogenic Properties:** It inhibits the NF- $\kappa$ B pathway and prevents new blood vessel formation, both of which are crucial for tumor growth.
- **Apoptosis Induction:** Through intrinsic and extrinsic pathways, L-Sulforaphane triggers cancer cell death, contributing to its role as a pro-apoptotic agent.

## Sinefungin

Sinefungin is a nucleoside antibiotic that inhibits S-adenosylmethionine (SAM)-dependent methyltransferases, affecting methylation processes critical for cancer cell survival. By modifying DNA, RNA, and protein methylation patterns, Sinefungin helps:

- **Reactivation of Tumor Suppressor Genes:** This mechanism disrupts the cancer cell's growth by preventing methylation-dependent silencing of these genes.
- **Antiviral and Antitumor Activities:** Sinefungin impairs viral RNA and protein synthesis and promotes apoptosis in cancer cells, which is particularly beneficial for tumors that display resistance to conventional therapies.

## Fumitremorgin C

Fumitremorgin C, a mycotoxin, functions as an ABC transporter inhibitor, preventing drug efflux and thereby increasing intracellular drug concentrations. It is especially effective in:

- **Overcoming Multidrug Resistance (MDR):** By inhibiting P-glycoprotein (P-gp) and other transporters, Fumitremorgin C helps retain therapeutic agents inside the cancer cells, enhancing their cytotoxic effects.
- **Inducing Apoptosis:** Fumitremorgin C's influence on cell transport pathways also leads to the activation of apoptotic pathways, making cancer cells more susceptible to treatment.

## Essential Amino Acids and Additional Compounds

In addition to these active ingredients, AminoSineTriComplex includes essential amino acids—L-Leucine, L-Tryptophan, L-Phenylalanine, and L-Lysine—which enhance neuronal stability, regulate neurotransmitter activity, and promote overall cell health. The complex is also fortified with natural compounds like EGCG, Genistein, Quercetin, Apigenin, and Berberine, which collectively promote apoptosis, arrest cell cycles, and interfere with cancer survival pathways.



## Experimental Validation

Studies on AminoSineTriComplex demonstrate its potent antitumor effects across several aggressive and MDR cancer cell lines. In vitro assays indicate a marked reduction in cancer cell viability and proliferation, with increased apoptosis rates in breast, prostate, and lung cancer models. These effects are confirmed by decreased matrix metalloproteinase (MMP) levels, suggesting inhibition of metastasis, and enhanced activation of natural killer (NK) cells, which further support the immune system's ability to target cancer cells.

## Clinical Implications and Future Directions

AminoSineTriComplex holds promise as an adjunct therapy in cancer treatment. By addressing MDR, promoting apoptosis, and enhancing immune responses, it offers a multifaceted approach to cancer care. Further studies are needed to explore its full therapeutic potential in vivo and its efficacy across diverse cancer types. As a sustainable solution integrating natural compounds with traditional approaches, AminoSineTriComplex may serve as a key component in modern cancer therapy.

**Bacteriophage Therapy: A Targeted Approach for Combating Antibiotic-Resistant Infections** (The formula for This Bacteriophage was developed by Professor Alexandre Tavartkiladze).

*Introduction:* With the rise in antibiotic-resistant bacterial infections, the need for effective alternatives to traditional antibiotics has become a priority in modern medicine. Among these alternatives, bacteriophage therapy has gained renewed interest for its potential to specifically target and eliminate antibiotic-resistant bacteria without disrupting the body's beneficial microbiota. Bacteriophages, or phages, are viruses that infect and destroy specific bacteria, acting as "natural predators" of bacterial pathogens. This precision makes bacteriophages especially valuable for treating infections caused by multidrug-resistant (MDR) strains that are no longer responsive to standard antibiotic treatments.

A notable development in this field is the Caucasian-origin bacteriophage (DSMZ accession number DSM 33404), designed to combat a variety of resistant bacteria commonly associated with healthcare-associated infections. Developed by Professor Alexandre Tavartkiladze, this bacteriophage shows great promise against *Staphylococcus aureus*, *Pseudomonas aeruginosa*, *Klebsiella pneumoniae*, and *Escherichia coli*—all of which are among the leading pathogens responsible for hospital-acquired infections.

## Mechanism of Action

The Caucasian-origin bacteriophage operates through a highly specific mechanism, targeting bacterial cells with remarkable precision. Upon encountering a susceptible bacterial cell, the phage attaches itself to the cell surface using specialized receptor-binding proteins. Once attached, the phage injects its genetic material into the bacterial cell, hijacking the cell's machinery to replicate itself. This replication process leads to the production of new phage

particles, which accumulate within the bacterial cell until the cell ruptures, releasing the newly formed phages to infect additional bacteria. This lytic cycle enables the phage to effectively reduce bacterial populations, providing a targeted approach to bacterial control.

The specificity of bacteriophages is a key advantage over antibiotics, which tend to act broadly and may harm beneficial bacteria within the human microbiome. In contrast, phages target only specific bacterial strains, preserving the balance of healthy bacteria and minimizing potential side effects associated with microbiome disruption. This characteristic makes bacteriophages a compelling solution, especially in patients who require long-term treatment for chronic infections.

## Clinical Applications and Efficacy

The therapeutic applications of the Caucasian-origin bacteriophage have been studied across a range of antibiotic-resistant infections. Clinical trials and case studies have shown promising results in treating infections such as furunculosis, osteomyelitis, septicemia, wound infections, and other challenging bacterial diseases. In one study, patients with chronic infections resistant to multiple antibiotics received bacteriophage therapy, leading to notable reductions in infection severity and, in many cases, complete remission.

These findings highlight the potential of bacteriophage therapy to serve as a primary treatment or adjunct to traditional antibiotics. When used alongside antibiotics, bacteriophages can enhance the effectiveness of the treatment by reducing bacterial loads, thereby helping to overcome resistance mechanisms. Additionally, bacteriophage therapy may provide a viable option for patients who cannot tolerate certain antibiotics due to allergies or adverse side effects, offering a tailored approach that addresses individual patient needs.

## Safety and Tolerability

One of the notable aspects of bacteriophage therapy is its favorable safety profile. Because phages are highly specific to their target bacteria, they pose minimal risk to human cells. Furthermore, as naturally occurring viruses in the environment, phages have coexisted with humans for millennia, with no evidence of causing harm to the human body under controlled therapeutic use. Clinical trials have reported few side effects, most of which are mild and transient, such as localized inflammation at the injection site. These results suggest that bacteriophage therapy can be safely administered, even over extended periods, making it suitable for managing chronic and recurring infections.

## Potential Role in Pandemic Preparedness and Infection Control

Bacteriophage therapy's relevance extends beyond individual cases to the broader context of pandemic preparedness and infection control. In settings where rapid transmission of resistant bacterial infections is a risk, such as hospitals and

nursing homes, bacteriophages can serve as a proactive measure to control outbreaks. Their ability to rapidly adapt to bacterial evolution, coupled with their precision in targeting specific bacteria, makes bacteriophages well-suited for managing resistant strains in high-risk environments.

Additionally, bacteriophages could complement antibiotic stewardship programs by offering an alternative treatment path that reduces reliance on antibiotics, slowing the development of resistance over time.

(19) 	(11)  EP 3 928 782 A1
(12) EUROPEAN PATENT APPLICATION	
(43) Date of publication: 29.12.2021 Bulletin 2021/52	(51) Int. Cl.: A61K 35/76 (2015.01) A61P 31/04 (2006.01) C12N 7/00 (2006.01)
(21) Application number: 21163701.2	
(22) Date of filing: 19.03.2021	
(54) Designated Contracting States: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR Designated Extension States: BA ME Designated Validation States: KH MA MD TN	(72) Inventors: • Tavartkiladze, Prof. Alexandre 0159 Tbilisi (GE) • Mchedlishvili, Valerian 0159 Tbilisi (GE)
(30) Priority: 20.03.2020 EP 20164862	(74) Representative: Rommeswinkel, Marika Von Rohr Patentanwälte Partnerschaft mbB Rütenscheider Straße 62 45130 Essen (DE)
(71) Applicant: Phagegroup LLC 0159 Tbilisi (GE)	
(54) BACTERIOPHAGE BASED THERAPY	
(57) The present invention relates to the medical field of treating bacterial infections. In particular, the present invention relates to a bacteriophage therapy of the treatment of bacterial infections and/or infectious diseases. In this context, the present invention discloses a specific	bacteriophage DSM 33404, capable of infecting bacteria and having lytic activity against bacteria, as well as a pharmaceutical composition containing said bacteriophage for the use in the treatment of bacterial infections and/or infectious diseases.

EP 3 928 782 A1

Printed by Jouve, 75001 PARIS (FR)

### Future Directions and Research Needs

While bacteriophage therapy shows tremendous promise, further research is needed to fully unlock its potential. Key areas of interest include optimizing phage delivery methods, developing phage “cocktails” for broader coverage against diverse bacterial strains, and conducting large-scale clinical trials to confirm efficacy across different infection types. The development of regulatory frameworks for bacteriophage therapy will also be essential to facilitate its safe and widespread use in clinical practice.

### Conclusion

The Caucasian-origin bacteriophage, developed under the leadership of Professor Alexandre Tavartkiladze, represents a groundbreaking advance in the fight against antibiotic-resistant bacterial infections. Its ability to target specific pathogens with precision, coupled with a favorable safety profile, positions bacteriophage therapy as a viable alternative or complement to traditional antibiotics. As the world faces a growing crisis of antimicrobial resistance, bacteriophage therapy offers a sustainable, adaptable, and patient-centered solution that aligns with the principles

of personalized medicine. Further research and clinical validation will be essential to integrate this promising therapy into mainstream medical practice, offering hope for patients affected by challenging bacterial infections.

### Conclusion: A Visionary Leader in Medicine and Research

Professor Alexandre Tavartkiladze’s role as Medical Director exemplifies the integration of clinical expertise, research innovation, and educational leadership. His contributions to oncology, phage therapy, and precision medicine have had a profound impact on patient care and scientific discovery. Through his work at the Institute for Personalized Medicine of Georgia, Professor Tavartkiladze is shaping the future of healthcare both locally and internationally.

With a commitment to personalized care, global collaboration, and sustainable healthcare solutions, Professor Tavartkiladze continues to lead the Institute toward new frontiers in medical science. His legacy of innovation, education, and compassionate care ensures that the Institute will remain a model of excellence for generations to come.



## Scientific Director: Professor Gaiane Simonia – A Leader in Medical Education and Research Innovation

Professor Gaiane Simonia, the Scientific Director of the Institute for Personalized Medicine of Georgia, has built a distinguished career as a medical educator, researcher, and mentor, with expertise spanning clinical pharmacology, chronic disease management, and personalized medicine. Her leadership has been instrumental in developing the Institute's research portfolio, fostering international collaborations, and mentoring the next generation of medical professionals and scientists. Through her visionary approach to education and interdisciplinary research, Professor Simonia has established herself as a pivotal figure in Georgia's healthcare system and a key contributor to global medical research.

### Educational Background and Professional Expertise

Professor Simonia's academic journey began at Tbilisi State Medical University (TSMU), where she earned her degrees with distinction, specializing in clinical pharmacology and chronic disease management. Her education laid a solid foundation for her future work in personalized healthcare, focusing on tailoring treatments to individual patient profiles. Over the years, Professor Simonia has expanded her expertise through collaborations with international institutions, gaining valuable experience in multidisciplinary research and innovative clinical practices. Her work emphasizes integrating pharmacological research with clinical applications, ensuring that the latest scientific discoveries are translated into effective healthcare solutions. Her deep understanding of chronic diseases, metabolic disorders, and the impact of infections such as COVID-19 on long-term health outcomes has been central to the Institute's success in both clinical care and research.

### Leadership in Research and Personalized Medicine

As the Scientific Director of the Institute for Personalized Medicine, Professor Simonia leads several cutting-edge research initiatives, focusing on chronic disease management, oncology, and post-COVID syndrome care. Under her guidance, the Institute has become a leader in exploring the intersection of the microbiome, immune function, and metabolic health, particularly in relation to cancer therapy and personalized pharmacology. Her recent work has focused on the biochemical impact of SARS-CoV-2 infection and its long-term effects on cardiovascular health, metabolic disorders, and cancer risk. These studies have made significant contributions to the global understanding of post-COVID syndrome and have shaped the development of personalized care protocols for recovering patients. Her research emphasizes the need for individualized interventions that consider each patient's unique biochemical and genetic profile.

Professor Simonia's expertise also extends to oncology, where she works closely with her team on integrating personalized cancer therapies with advanced diagnostic tools like liquid biopsy technologies. Her focus on personalized pharmacology ensures that treatments are tailored to each patient's molecular and genetic characteristics, optimizing

therapeutic outcomes and minimizing side effects.

### Educational Leadership and Mentorship

In addition to her role as Scientific Director, Professor Simonia is a passionate educator and mentor. She plays a critical role in training and developing young scientists, medical students, and healthcare professionals, ensuring that the next generation of medical innovators is equipped with the knowledge and skills needed to excel in precision medicine. Her mentorship emphasizes critical thinking, interdisciplinary collaboration, and the application of evidence-based medicine. Through her partnership with Tbilisi State Medical University, Professor Simonia has helped establish faculty development programs that provide continuing education opportunities for clinicians and researchers. These programs include workshops, seminars, and online learning modules designed to keep healthcare professionals abreast of the latest advances in clinical research, pharmacology, and healthcare management. Her efforts to foster global academic collaborations have led to partnerships with renowned institutions, including Gustave Roussy in France, Hiroshima University in Japan, Melbourne University Clinics in Australia, and the London Cancer Center. These partnerships enable knowledge exchange, joint research projects, and the development of new treatment protocols that benefit both local and international communities.

### Global Collaborations and Research Impact

Professor Simonia's commitment to international collaboration ensures that the Institute remains at the forefront of global medical research. By fostering partnerships with leading academic institutions and research centers, she has created a platform for the exchange of ideas and expertise, enriching the Institute's research portfolio and expanding its global influence. The Institute's participation in international clinical trials and research consortia is a testament to her leadership. These collaborations provide patients with access to innovative therapies and enable the Institute to contribute to the development of cutting-edge treatments. Her work has been presented at international conferences and published in peer-reviewed journals, reinforcing the Institute's position as a leader in personalized medicine.

### A Vision for Sustainable Healthcare

Professor Simonia's vision for the Institute is rooted in the principles of sustainability, personalized care, and interdisciplinary collaboration. She advocates for healthcare solutions that are tailored to individual patient needs, emphasizing the importance of early intervention, personalized pharmacology, and integrative therapies. Her research on the microbiome and immune system offers new insights into chronic disease management, helping to develop comprehensive care plans that address both acute symptoms and long-term health outcomes. Her leadership ensures that the Institute remains a model of excellence in both education and research, contributing to the advancement of healthcare on a global scale. Through her commitment to mentorship and collaboration, Professor Simonia inspires the next

generation of medical professionals to push the boundaries of medical science and develop innovative healthcare solutions.

### Conclusion: A Visionary in Medical Education and Research

Professor Gaiane Simonia exemplifies the integration of scientific research, clinical care, and medical education. As the Scientific Director of the Institute for Personalized Medicine of Georgia, she has played a pivotal role in shaping the Institute's research agenda and fostering international collaborations. Her work in chronic disease management, post-COVID care, and personalized oncology reflects a deep commitment to improving patient outcomes and advancing global healthcare. Through her educational leadership, mentorship programs, and research initiatives, Professor Simonia ensures that the Institute remains at the forefront of personalized medicine. Her focus on sustainability, interdisciplinary collaboration, and patient-centered care positions the Institute as a leader in medical innovation, benefiting patients both in Georgia and worldwide.

The Clinical and Genetic Laboratory Research Unit: A Foundation of Scientific Innovation and Precision Medicine.

A cornerstone of the Institute for Personalized Medicine of Georgia is its Clinical and Genetic Laboratory Research Unit, which plays a crucial role in supporting the Institute's precision medicine initiatives and clinical diagnostics. Under the leadership of Dr. Rusudan Khutsishvili, the laboratory has become a hub of innovative research, diagnostics, and therapeutic development, ensuring that the Institute remains at the forefront of molecular medicine and personalized healthcare. The laboratory is staffed by a multidisciplinary team of experienced researchers and clinicians, including Tsitsino Javakhishvili, Lali Chikhladze, Ioseb Todua, Eka Moseshvili, and Veriko Khachapuridze. This highly skilled team ensures that the laboratory operates at the highest standards, combining clinical expertise with advanced research techniques to address some of the most pressing challenges in healthcare today.

### Cutting-Edge Equipment and Technology for Advanced Research

The Clinical and Genetic Laboratory Research Unit is fully equipped with state-of-the-art clinical, biochemical, and immunological analyzers, providing the foundation for highly accurate diagnostics and innovative research. The laboratory's advanced technological infrastructure includes:

- Clinical blood analyzers and coagulometers for comprehensive hematology studies.
- Complete biochemical and immunological analyzers for precise metabolic and immune system assessments.
- Automatic ELISA (Enzyme-Linked Immunosorbent Assay) and ECLIA (Electro-Chemiluminescence Immunoassay) technologies to detect hormones, proteins, and antibodies.
- Fluorescent microscopy and immunogenetics systems to investigate molecular markers and immune responses.

The laboratory's integration of advanced diagnostics with clinical applications ensures timely and precise treatment

decisions, supporting the Institute's focus on personalized oncology and chronic disease management.

### Specialized Tools for Molecular Research: DNA and Stem Cell Technologies

The laboratory houses specialized equipment for DNA research and cellular studies, reflecting its focus on genomics, molecular diagnostics, and immunotherapy. These tools include:

- DNA scanners for genomic analysis and personalized treatment design.
- The Cell Search system, used to isolate and analyze circulating tumor cells (CTCs) and cell-free DNA (ctDNA), providing critical information for early cancer detection and treatment monitoring.
- A laboratory of cell cultures and chronobiology, exploring the role of biological rhythms in cancer progression and chronic disease.

The facility is equipped with next-generation sequencing (NGS) technologies, as well as RT-PCR and qPCR systems, enabling detailed investigations of genetic mutations, infectious agents, and biomarkers. The inclusion of a DNA synthesis machine for the production of primers further reflects the laboratory's ability to conduct advanced genetic research independently.

### Innovative Research in Oxidative Stress and Immunotherapy

In line with the Institute's commitment to translational research, the laboratory has developed specialized departments to explore the molecular underpinnings of disease. The laboratory features:

- **Micro and macro systems for oxidative stress research**, focusing on the role of **reactive oxygen species (ROS)** in cancer progression and chronic disease development.
- **A department dedicated to the production and processing of CAR-T cells**, advancing the Institute's capabilities in **personalized immunotherapy**. CAR-T cell therapy represents a breakthrough in **cancer treatment**, offering targeted and durable solutions for patients with certain hematological malignancies.

These innovations highlight the laboratory's role as a driving force behind the Institute's therapeutic strategies, ensuring that the latest advancements in immunology and molecular biology are incorporated into clinical care.

### The Importance of a Strong Scientific and Practical Base

The Clinical and Genetic Laboratory Research Unit embodies the Institute for Personalized Medicine's commitment to excellence in research and diagnostics. Its integration of advanced molecular tools, cutting-edge technology, and a multidisciplinary research team allows the Institute to bridge the gap between laboratory science and patient care. Through collaborative research efforts, clinical trials, and personalized treatment protocols, the laboratory ensures that every patient benefits from the latest scientific advancements.

The presence of a comprehensive DNA research department, combined with specialized facilities for cell culture and CAR-T cell production, reflects the Institute's ambition to remain at the forefront of precision medicine and personalized healthcare. The laboratory not only enhances the Institute's ability to deliver innovative therapies but also contributes to global research initiatives, solidifying its role as a center of excellence in Georgia and abroad.

### Conclusion: A Hub of Innovation and Clinical Excellence

The Clinical and Genetic Laboratory Research Unit serves as the scientific backbone of the Institute for Personalized Medicine of Georgia, playing a crucial role in both research innovation and clinical care. With advanced technological infrastructure and a highly qualified team of researchers, the laboratory supports the Institute's mission to provide personalized, evidence-based healthcare.

Through its focus on genomics, immunology, chronobiology, and molecular diagnostics, the laboratory ensures that the Institute remains at the forefront of modern medicine, capable of developing innovative solutions to the most challenging medical problems. Whether through CAR-T cell production, DNA sequencing, or liquid biopsy technologies, the Clinical and Genetic Laboratory Research Unit demonstrates the Institute's commitment to delivering high-quality patient care based on scientific excellence and innovation.

The laboratory's capabilities reflect the Institute's strategic importance within Georgia's healthcare system and its contributions to global healthcare advancements, ensuring that it continues to lead the way in personalized medicine.

### Clinical Oncology, Hematology, Internal Medicine, Medical Genetics, Pharmacology, and Radiology Unit: Excellence in Multidisciplinary Care

The Clinical Oncology, Hematology, Internal Medicine, Medical Genetics, Pharmacology, and Radiology Unit at the Institute for Personalized Medicine of Georgia embodies the Institute's commitment to comprehensive patient care and multidisciplinary collaboration. This unit integrates cutting-edge clinical services, innovative therapeutic approaches, and personalized medicine, ensuring world-class treatment for every patient. The department is led by Dr. Pati Revazishvili, a highly respected physician whose clinical expertise and leadership have established the unit as a center of excellence for precision healthcare.

Supported by an accomplished team of doctors, professors, and healthcare professionals, the unit provides therapeutic oncology, hematology, internal medicine (Including Cardiology, Nephrology, Rheumatology, Clinical Immunology, Hepato-Gastro-Enterology, Pulmonology...), pharmacology, and genetic consulting services. Each discipline works in tandem, leveraging the latest research, diagnostic tools, and therapeutic protocols to address complex medical conditions.

### A Team of Experts Dedicated to Multidisciplinary Patient Care

The department is staffed by an exceptional group of doctors and healthcare professionals, including:

- Professor Gaiane Simonia, a leading figure in Internal Medicine, Cardiology and personalized healthcare.
- Professor Alexandre Tavartkiladze, a leading figure in Medical Oncology, Hematology, Internal Medicine and Clinical Genetics
- Professor Irine Andronikashvili, known for her expertise in Internal Medicine, Cardiology and chronic disease management.
- Dr. Maia Maisuradze - Medical Oncology, Radiology (X-Ray)
- Dr. George Mamukashvili - Radiology (Ultrasonography), Cardiology
- Dr. Tatia Potskhoraiia Medical Oncology
- Dr. Tamar Japaridze - Medical Oncology
- Dr. Besik Begashvili specialist in critical care.
- Professor Pirdara Nozadze, Internal Medicine, Cardiology

The unit also benefits from a dedicated nursing team—including Nino Uriadmkofeli, Nino Qsovreli, Tamar Kudukhova, and Maia Chokhoniidze—who provide compassionate care and patient support. Pharmacy services are led by Dr. Nani Turmanidze, ensuring that each patient receives the most appropriate pharmacological interventions based on their individualized treatment plans. This multidisciplinary team collaborates closely to optimize patient outcomes, providing integrated care that addresses all aspects of a patient's health—from oncology and internal medicine to genetics and pharmacology.

**Comprehensive Medical Services Across Multiple Specialties**  
The department offers a full spectrum of services across several key medical specialties, including:

- **Oncology and Hematology:** Advanced cancer therapies, personalized chemotherapy protocols, and hematological treatments for conditions such as lymphomas, leukemias, and myelomas.
- **Internal Medicine:** Specialized care in cardiology, rheumatology, nephrology, gastroenterology, pulmonology, and immunology. This ensures that patients receive comprehensive management for chronic conditions alongside their primary treatments.
- **Medical Genetics:** Genetic counseling and precision diagnostics, focusing on hereditary diseases, oncogenomics, and personalized treatment algorithms.
- **Clinical Pharmacology:** Consulting and management of pharmacological interventions tailored to individual genetic profiles to minimize side effects and enhance therapeutic efficacy.
- **Radiology and Diagnostic Imaging:** Use of advanced imaging technologies to monitor treatment responses and detect early disease progression.

This multidisciplinary approach ensures that every patient receives personalized and holistic care tailored to their specific medical needs. The unit's ability to integrate multiple specialties within one framework allows for seamless coordination between diagnostics, treatments, and follow-up care.

International Collaboration and Global Consulting Platforms  
The Clinical Oncology and Hematology Unit stands out not only for its exceptional patient care but also for its global collaborations with leading healthcare institutions, including:

- **Gustave Roussy in France**
- **London Cancer Center in the United Kingdom**
- **Hiroshima University in Japan**
- **Melbourne University Clinics in Australia**

These partnerships enable the department to exchange knowledge, participate in clinical trials, and apply the latest medical advancements in its treatment protocols. Through these international consulting platforms, the department receives expert opinions on complex cases, ensuring that patients benefit from the most advanced therapies available worldwide. The unit's collaborative research initiatives also enhance its international reputation, contributing to the development of innovative therapeutic approaches and personalized care models. These global partnerships reflect the department's commitment to evidence-based medicine and its dedication to staying at the forefront of medical science.

### **Patient Outcomes, Clinical Research, and International Impact**

The success of the Clinical Oncology, Hematology, and Internal Medicine Unit is reflected in the positive outcomes of its patients and its growing international recognition. The unit's focus on precision medicine including the use of liquid biopsy technologies for early cancer detection has led to remarkable treatment successes. The department consistently achieves high cure and remission rates, contributing to international interest in its treatment protocols. The unit also plays a key role in the Institute's research efforts, producing clinically relevant publications that are widely cited in peer-reviewed journals. The high impact and diverse range of topics covered in these publications demonstrate the department's scientific rigor and innovative thinking. By addressing subjects ranging from cancer genomics to pharmacological interventions, the department contributes to the global body of knowledge on personalized healthcare.

### **A Model for Multidisciplinary Healthcare Excellence**

The Clinical Oncology, Hematology, Internal Medicine, Medical Genetics, Pharmacology, and Radiology Unit exemplifies the Institute for Personalized Medicine's mission to deliver comprehensive, patient-centered care. Through its integration of multiple specialties, commitment to personalized treatment protocols, and active international collaborations, the unit sets a new standard for multidisciplinary healthcare in Georgia and beyond. The success of the department lies in its ability to combine clinical excellence with innovative research. Each patient benefits from personalized care plans designed to address not only their primary conditions but also underlying comorbidities. This holistic approach ensures that patients receive the most effective treatments while maintaining a high quality of life.

### **Overview of Textbooks and Monographs Published by the Working Group of the Institute of Personalized Medicine Until 2024**

Here is an overview of the textbooks and monographs published by the Working Group of the Institute of Personalized Medicine until 2024, translated into English with a brief description for each:

#### **1. Neurology, Endocrinology, and Immune System Roles in Nervous System Pathologies**

- **Authors:** Alexandre Tavartkiladze, Teimuraz Petriashvili
- **Description:** This book explores the intersections of neurology, endocrinology, and immunology, focusing on their roles in nervous system disorders. It provides insights into the physiological and pathological processes involved in these complex interactions, making it a valuable resource for both students and practitioners.

#### **2. Philosophy, Ecology, and Spirituality**

- **Author:** Alexandre Tavartkiladze
- **Description:** This monograph examines the relationship between philosophy, ecology, and spirituality. It discusses human interaction with nature and explores philosophical concepts related to the environment and human existence, fostering a deeper understanding of humanity's connection to the natural world.

#### **3. Molecular and Cellular Oncology**

- **Authors:** Alexandre Tavartkiladze, Dinara Kasradze
- **Description:** Focused on cellular and molecular aspects of cancer, this book provides a detailed look at the cellular mechanisms and molecular pathways involved in oncogenesis. It is an essential resource for researchers and healthcare professionals studying or working in cancer research and treatment.

#### **4. Melatonin and Cardiovascular Physiology**

- **Authors:** Alexandre Tavartkiladze, Gaiane Simonia
- **Description:** This book discusses the role of melatonin in cardiovascular health, covering its physiological effects and potential therapeutic applications. It highlights melatonin's influence on heart health and related physiological systems, offering insights into its preventive and treatment potential.

#### **5. Ad Augusta per Augusta: Obstacles, Challenges, and Resilience**

- **Authors:** Alexandre Tavartkiladze, Dinara Kasradze
- **Description:** A philosophical work reflecting on the human spirit's journey through challenges and hardships, encapsulating the phrase "To greatness through difficulties." This book provides motivational insights based on historical and contemporary examples of resilience and perseverance.

#### **6. Cancer: Causes, Mechanisms of Development, Prevention**

- **Authors:** Alexandre Tavartkiladze, Rema Gvamichava
- **Description:** This monograph provides a comprehensive exploration of the causes and mechanisms behind the development of malignant tumors. It delves into the



etiopathogenesis of cancer, offering insights into preventive strategies and risk factors, making it suitable for researchers, students, and healthcare professionals.

### 7. Novogen: Bioactive Natural Molecules in Oncology


- **Authors:** Alexandre Tavartkiladze, Dea Kolbaia
- **Description:** This monograph explores the role of bioactive natural molecules in oncology. It provides an in-depth analysis of how these natural compounds can be harnessed in cancer treatment, focusing on their therapeutic potential and mechanisms of action. It is a valuable resource for those




interested in alternative and integrative approaches in oncology.



### 8. Melatonin: Biological Aspects and Clinical Perspectives

- **Author:** Alexandre Tavartkiladze

- **Description:** This book delves into the biological functions of melatonin and its clinical applications. It provides insights into melatonin's role in human health, covering both its physiological effects and therapeutic potential for various medical conditions.







## Conclusion

The textbooks and monographs published by the Working Group of the Institute of Personalized Medicine reflect a multidisciplinary approach to understanding human health. Covering subjects from oncology and neurology to the philosophy of resilience and natural therapies, these works aim to bridge the gap between traditional and modern medical practices, fostering a comprehensive understanding of personalized and integrative medicine. They serve as valuable resources for students, practitioners, and researchers alike, offering knowledge and insights across a diverse range of scientific and philosophical topics.

## Upcoming Publications in Medicine and Biology: Key Textbooks and Monographs from the Institute of Personalized Medicine (2024-2025)

Here is a brief overview of the textbooks and monographs set to be published by the Working Group of the Institute of Personalized Medicine in 2024-2025:

### 1. Clinical Oncology

- **Author:** Professor Alexandre Tavartkiladze
- **Description:** This comprehensive textbook provides an in-depth exploration of oncology, focusing on the latest advancements in cancer treatment, diagnostic techniques, and personalized approaches. It serves as a crucial resource for both students and practitioners in the field.

### 2. A Misconception of Evolutionary Theory: Facts, Arguments, and Evidence

- **Author:** Alexandre Tavartkiladze
- **Description:** This book challenges common misconceptions about evolutionary theory, presenting evidence-based arguments and discussions on the complexities of evolution. It is an informative read for students and researchers interested in evolutionary biology and anthropology.

### 3. Human Developmental Biology: The Molecular Basis of Obstetrics and Gynaecology

- **Authors:** Alexandre Tavartkiladze, Veriko Baziari
- **Description:** This textbook delves into the molecular aspects of human development, particularly focusing on the

fields of obstetrics and gynecology. It is designed for medical students and professionals seeking a molecular perspective on developmental biology.

### 4. Fundamental and Clinical Haematology

- **Authors:** Alexandre Tavartkiladze, Nino Sharashenidze
- **Description:** This book covers the fundamental principles and clinical aspects of hematology, offering insights into blood disorders, their diagnosis, and treatment. It is essential reading for students, clinicians, and researchers in hematology.

### 4. Internal Medicine

- **Authors:** Alexandre Tavartkiladze, Gaiane Simonia
- **Description:** A detailed guide to the field of internal medicine, this textbook addresses a wide range of medical conditions, diagnostic tools, and therapeutic approaches. It is intended for medical students and practitioners aiming to enhance their knowledge in general medicine.


### 5. Melatonin, Biological Rhythms, and a Guide to Proper Nutrition and Healthy Living

- **Authors:** Alexandre Tavartkiladze, Dinara Kasradze
- **Description:** This book explores the role of melatonin and biological rhythms in maintaining health, with additional guidance on nutrition and lifestyle. It is a valuable resource for those interested in holistic health and preventive medicine.



### 6. Personalised Medicine: Essential Knowledge for All



- **Authors:** Alexandre Tavartkiladze, Gaiane Simonia
- **Description:** This accessible guide introduces the concepts and applications of personalized medicine, focusing on tailored approaches in patient care. It is ideal for healthcare professionals, students, and anyone interested in the future of medical practice.

These publications provide a rich foundation of knowledge for students, professionals, and researchers, with topics spanning oncology, evolutionary theory, developmental biology, hematology, internal medicine, melatonin research, and personalized medicine.









### Advancing Healthcare Through Expertise and Innovation

Under the leadership of Dr. Pati Revazishvili, the Clinical Oncology, Hematology, Internal Medicine, and Genetics Unit continues to drive innovation and clinical excellence. Through its expert team, advanced diagnostic tools, and international collaborations, the department delivers world-class healthcare that meets the highest standards of precision medicine. The unit's achievements in clinical care and research—combined with its global partnerships and growing influence—ensure that it remains a leader in personalized medicine. As part of the Institute for Personalized Medicine of Georgia, this department plays a vital role in shaping the future of healthcare, providing patients with comprehensive, cutting-edge treatments designed to meet the challenges of the 21st century.

### Nobel-Worthy Contributions in Personalized Medicine: Advancing Cancer, Antimicrobial Resistance, and Post-COVID Care

The work of the Institute for Personalized Medicine of Georgia, particularly under the leadership of Professors Alexandre Tavartkiladze and Gaiane Simonia, exhibits qualities that could indeed attract the interest of the Nobel Committee. Their pioneering research in personalized medicine integrates groundbreaking therapeutic approaches, addressing critical global healthcare challenges such as cancer, antimicrobial resistance, and post-COVID-19 health impacts. This synthesis of innovation, patient-centered care, and international collaboration positions the Institute as a formidable force in advancing modern medicine.

One area of significant Nobel-worthy potential is their research on the melatonin-microbiome axis and its application in oncology. Professor Tavartkiladze's exploration of circadian rhythms and melatonin's impact on cancer progression is transformative. By examining how disruptions in circadian patterns can affect tumor growth and immune response, the team has paved the way for melatonin-based therapies that synchronize treatment schedules with patients' biological clocks, particularly benefiting those with aggressive cancers like triple-negative breast cancer (TNBC). This research aligns with the Nobel Prize's tradition of acknowledging discoveries that deepen our understanding of physiological processes and open new therapeutic possibilities. If this approach continues to demonstrate efficacy in clinical outcomes, it could represent a significant advancement in oncology and circadian biology.

Additionally, the Institute's work on phage therapy for combating antimicrobial resistance (AMR) is another candidate for Nobel interest. Professor Tavartkiladze's European patent for a Caucasian-origin bacteriophage therapy exemplifies a novel approach to addressing a pressing global issue. Unlike broad-spectrum antibiotics, which can lead to resistance and disrupt beneficial microbiota, this targeted therapy utilizes bacteriophages specific to multi-drug-resistant pathogens. This innovation

offers a sustainable and tailored alternative to traditional antibiotics, underscoring the Nobel Committee's focus on solutions that promise to reshape global health practices. Phage therapy's potential impact on public health, especially if widely adopted, could position it as a revolutionary solution for AMR, a key public health threat.

In response to the COVID-19 pandemic, the Institute's contributions to understanding and managing post-COVID syndrome also reflect Nobel-worthy innovation. Professor Simonia's leadership in uncovering the long-term biochemical impacts of SARS-CoV-2—particularly its effects on cardiovascular health, cancer risk, and metabolic disorders—has informed the development of personalized treatments for post-COVID patients. These findings provide insights into managing chronic disease risks following viral infections, an area increasingly relevant to global health. Their work aids healthcare systems worldwide in preparing for the lasting consequences of COVID-19, an effort that could resonate strongly with the Nobel Committee's interest in scientific research that addresses large-scale health challenges.

The Nobel Prize has frequently honored individuals and teams that foster interdisciplinary collaboration, a strength of the Institute. Their partnerships with world-leading institutions such as Gustave Roussy in France and Hiroshima University in Japan demonstrate a commitment to global scientific exchange. Through clinical trials and knowledge sharing, the Institute remains at the forefront of medical advancements, bringing cutting-edge treatments to Georgian patients and contributing to global research. This dedication to collaboration and innovation in medical science exemplifies the values Nobel recognition often celebrates.

Education and mentorship are central to the Institute's mission, with programs that train the next generation of medical professionals in personalized and precision medicine. This emphasis on scientific inquiry, led by Professors Tavartkiladze and Simonia in collaboration with Tbilisi State Medical University, ensures that the Institute's innovative approaches will have lasting impacts, equipping young clinicians with the skills needed to advance global healthcare standards.

In conclusion, the Institute for Personalized Medicine of Georgia is undertaking research and clinical applications that align with the Nobel Committee's focus on groundbreaking advancements in health and human welfare. Their work in melatonin-based cancer therapies, phage therapy, and post-COVID health management exemplifies the kind of pioneering research that has the potential to reshape healthcare globally. With contributions recognized by Nobel laureate reviewers, the Institute's achievements attract increasing attention within the scientific community and beyond, embodying the transformative impact that defines Nobel-worthy research [1-27].

## 2. Conclusion

### The Institute for Personalized Medicine of Georgia – Advancing Precision Healthcare and Global Research Collaboration

The Institute for Personalized Medicine of Georgia stands as a beacon of scientific advancement and personalized healthcare, setting a new standard in precision medicine for the Georgian healthcare landscape and beyond. With a foundation rooted in interdisciplinary research, patient-centered care, and global collaborations, the Institute has transformed the way healthcare is delivered, integrating the latest scientific breakthroughs with innovative treatment protocols. The work undertaken by the Institute, under the leadership of prominent experts such as Professors Alexandre Tavartkiladze and Gaiane Simonia, has not only addressed critical health challenges in Georgia but has also contributed to international medical knowledge and collaboration.

One of the Institute's most significant achievements is its role in advancing oncology care within Georgia. The integration of personalized medicine into oncology has allowed the Institute to treat thousands of cancer patients with therapies tailored to their individual genetic, biological, and environmental factors. This personalized approach to treatment has led to improved outcomes, reducing hospital stays and minimizing adverse effects, while also optimizing the allocation of healthcare resources. As a result, the Institute has become a crucial player in Georgia's healthcare system, offering an innovative model for other institutions to follow.

The Institute's collaborative efforts with leading international medical institutions such as Gustave Roussy in France, the London Cancer Center, Hiroshima University in Japan, and Melbourne University Clinics in Australia have amplified its impact. These partnerships enable the Institute to remain at the forefront of medical advancements by participating in clinical trials, sharing knowledge, and implementing cutting-edge therapies. Georgian patients benefit directly from these collaborations, gaining access to the latest treatments and research developments that would otherwise be unavailable. The Institute's active involvement in global medical research also showcases its commitment to contributing to solutions for some of the most pressing healthcare challenges worldwide.

One area where the Institute has made groundbreaking contributions is in melatonin research, particularly its role in oncology. Professor Tavartkiladze's exploration of the melatonin-microbiome axis has opened new avenues in cancer biology and treatment. His research has highlighted the influence of circadian rhythms on cancer progression and immune responses, leading to the development of melatonin-based therapies that align with patients' biological clocks. This innovative approach to chronotherapy has shown promise in improving outcomes for patients with aggressive forms of cancer, such as triple-negative breast cancer, marking a significant milestone in cancer treatment.

Phage therapy, another pioneering field championed by the Institute, represents a novel approach to combating antimicrobial resistance (AMR). With a European patent for phage therapy, Professor Tavartkiladze's research utilizes bacteriophages sourced from the Caucasus region to target multi-drug-resistant pathogens. This targeted therapy offers a sustainable and effective alternative to traditional antibiotics, addressing a growing global issue of AMR while preserving beneficial microbiota. The Institute's advancements in phage therapy position it as a leader in the field, contributing to global efforts to combat antibiotic-resistant infections and offering new hope for patients with chronic and complex infections.

In response to the COVID-19 pandemic, the Institute has also made significant strides in understanding and managing post-COVID syndrome. Led by Professor Simonia, the Institute's research has uncovered the long-term effects of SARS-CoV-2 infection on cardiovascular health, metabolic disorders, and cancer risk. These findings have informed the development of personalized treatment plans for patients recovering from COVID-19, addressing the biochemical changes that increase the risk of chronic conditions. The Institute's contributions in this area are invaluable, as they provide a foundation for healthcare systems worldwide to better manage the lasting health impacts of the pandemic.

Education and mentorship play a central role in the Institute's mission, as seen in its collaboration with Tbilisi State Medical University (TSMU). Through training programs, workshops, and seminars, the Institute fosters a culture of scientific inquiry and critical thinking among young healthcare professionals. Professors Tavartkiladze and Simonia's dedication to mentorship ensures that the next generation of Georgian doctors and researchers are well-equipped to excel in precision medicine. Additionally, the Institute's international partnerships facilitate exchange programs that expose students to global healthcare innovations, further enhancing their academic and professional development.

The Clinical and Genetic Laboratory Research Unit, directed by Dr. Rusudan Khutsishvili, exemplifies the Institute's commitment to integrating research with clinical care. Equipped with advanced technologies such as DNA sequencing, CAR-T cell production, and immunogenetic testing, this unit serves as the backbone of the Institute's personalized medicine initiatives. By providing cutting-edge diagnostics and supporting translational research, the laboratory ensures that scientific advancements are rapidly incorporated into patient care. This seamless integration of research and clinical practice reinforces the Institute's reputation as a leader in precision medicine.

The Institute's publications, including textbooks and monographs, further underscore its role as a thought leader in personalized and integrative medicine. These works, covering topics such as oncology, neurology, molecular biology, and philosophy, serve as invaluable resources for students, practitioners, and researchers worldwide. They reflect the Institute's multidisciplinary approach



to healthcare, bridging traditional and modern medical practices to foster a holistic understanding of human health. The upcoming publications, which include comprehensive guides on oncology, hematology, and internal medicine, will continue to contribute to the body of medical knowledge and support the education of future healthcare professionals.

In conclusion, the Institute for Personalized Medicine of Georgia has established itself as a model of excellence in modern healthcare. Through its dedication to personalized care, scientific research, and global collaboration, the Institute continues to make significant contributions to the fields of oncology, pharmacology, genetics, and chronic disease management. Its innovative approaches to healthcare challenges—whether through melatonin chronotherapy, phage therapy, or post-COVID syndrome research—are transforming patient care and shaping the future of precision medicine.

The Institute's commitment to education, patient-centered care, and sustainable healthcare solutions positions it as a vital player in Georgia's healthcare system and a respected contributor to international medical research. As it moves forward, the Institute for Personalized Medicine of Georgia will undoubtedly remain at the forefront of healthcare innovation, inspiring new generations of medical professionals and advancing global standards in personalized and integrative healthcare.

## References

1. Tavartkiladze, A. G., Simoniia, G. V., Kolbaia, D. T., Petriashvili, T. G. (2006). Biochemical and clinical aspects of melatonin biosynthesis induced by noradrenalin in experiment. *Georgian Medical News*, (133), 86-88.
2. Tavartkiladze, A. G., Simoniia, G. V., Kolbaia, D. T., Shalashvili, A. G., Petriashvili, T. G. (2006). Biochemical, pharmacological and clinical aspects of influencing methionine, tryptophan, pyridoxine (vitamin B6), Ca<sup>2+</sup> and high-calorie food on the synthesis and intensity of the secretion of melatonin. *Georgian medical news*, (132), 121-123.
3. Kasradze, D., Tavartkiladze, A., Kasradze, M., Nozadze, P. (2010). The study of melatonin protective activity on pancreatic beta-cells under the condition of alloxan-induced diabetes during aging. *Georgian Med News*, 189, 56-63.
4. Dzelashvili, N. O., Kasradze, D. G., Tavartkiladze, A. G., Mariamidze, A. G., Dzinchveladze, D. N. (2013). Expression of epidermal growth factor receptor and plasmatic level of melatonin in simple and complex endometrial hyperplasia. *Georgian Medical News*, (223), 91-95.
5. Dzelashvili, N., Kasradze, D., Tavartkiladze, A. (2014). Expression of epidermal growth factor receptor and concentrations of epidermal growth factor and melatonin in endometrial carcinoma. *Georgian Medical News*, (235), 17-24.
6. Dzelashvili, N., Kasradze, D., Tavartkiladze, A., Mariamidze, A. (2014). Epidermal growth factor receptor expression and epidermal growth factor blood plasma content in simple and complex endometrial hyperplasia. *Georgian Medical News*, (226), 59-65.
7. Tavartkiladze, A. A., Simonia, G. G. (2014). Melatonin secretion in patients with breast cancer associated with primary hypertension. *Annals of Oncology*, 25, v99.
8. Tavartkiladze, A., Petriashvili, T. (2014). Influence of melatonin on the rZR genes expression in the endothelial cells in patients with atherosclerosis. *Atherosclerosis*, 235(2), e135.
9. Tavartkiladze, A. (2014). The study of chemotherapeutic substances and combination of melatonin and methotrexate on the cellular culture of prostate cancer and clinical experience.
10. Tavartkiladze, A., Sordia, T. (2015). Expression of connexin 43 in primary liver cancer associated or not with hepatitis C and its relationship with resistance of chemotherapy.
11. Tavartkiladze, A. (2015). CTCs as early biomarkers of primary liver cancer in the patients with liver diseases.
12. Tavartkiladze, A., Khutsishvili, R., Gogiberidze, A. (2016). 1-Methylhistidine and high dose methotrexate influence on triple negative breast cancer in experiment. *European Journal of Cancer*, 1(61), S113.
13. Tavartkiladze, A., Khutsishvili, R., Gogiberidze, A. (2016). Messenger-RNA characteristics in triple negative breast cancer. *European Journal of Cancer*, 1(61), S165.
14. Tavartkiladze, A., Khutsishvili, R., Gogiberidze, A. (2016). Effects of telomerase blockage on the advanced triple negative breast cancer cells culture by activated lymphocytes. *European Journal of Cancer*, 1(61), S113.
15. Tavartkiladze, A., Simonia, G., Khutsishvili, R. (2017). Melatonin Inhibits the Metastatic Ability of HER2/neu-negative Breast Cancer Cells by Suppressing Epithelial-to-Mesenchymal Transition (EMT)-Associated Genes with Predictive and Prognostic Relevance. *Annals of Oncology*, 28, vii30.
16. Tavartkiladze, A., Simonia, G., Khutsishvili, R. (2017). Characteristics of Melatonin Receptor Gene (MLT1) Expression in Prostate Cancer. *Annals of Oncology*, 28, ix107.
17. Tavartkiladze, A., Gvajaia, A., Revazishvili, P. (2019). Chronobiological features of melatonin receptors (MT1) expression in breast cancer cells.
18. Revazishvili, P., Tavartkiladze, A., Tavartkiladze, L., Sordia, T., Gvajaia, A. (2019). Chronobiological assessment of triple-negative breast cancer.
19. Tavartkiladze, A. A., Khutsishvili, R., Revazishvili, P., Maisuradze, M., Tavartkiladze, L., et al. (2019). Treatment of refractory recurrent gastrointestinal stromal tumors with adoptive cellular immunotherapy (TILs) and personalized vaccine. *Annals of Oncology*, 30, xi13.
20. Tavartkiladze, A., Revazishvili, P., Gvajaia, A. (2019). Influence of agomelatine and trastuzumab on the HER2/neu (+), MT1 (+) and MT2 (+) chemo and immunoresistant breast cancer cells lines from the previously treated patients by targeted therapy with trastuzumab.
21. Tavartkiladze, A., Revazishvili, P., Potskhoraia, T., Tavartkiladze, L. (2023). Circulating Tumor Cells (CTCs), Melatonin, and uNOS: New Frontiers in Cancer Diagnosis

- and Treatment. *The Journal of Liquid Biopsy*, 1.
22. Tavartkiladze, A., Revazishvili, P., Maisuradze, M., Tavartkiladze, L., Potskhoraia, T., et al. (2023). Heterogeneity of Somatostatin Receptors on Circulating Tumor Cells in Neuroendocrine Tumors and Melatonin's Potential in Non-Small-Cell Lung Cancer. *The Journal of Liquid Biopsy*, 1.
23. Tavartkiladze, A., Simonia, G., Kasradze, D., Revazishvili, P., Egiazarov, D. (2023). Melatonin: The Nighttime Hormone's Role in Cancer Control and Immunity Enhancement. *JJ Oncol Clin Res*, 4, 1-13.
24. Tavartkiladze, A., Simonia, G., Lou, R., Revazishvili, P., Kasradze, D., et al. (2024). Targeting Glycolysis in Tumor Cells: Therapeutic Inhibition of GLUT1 and LDH-A Using Phloretin and Melatonin for Metabolic Reprogramming and Tumor Regression in Triple Negative Breast Cancer. *Immunogenet Open Access*, 9, 235.
25. Tavartkiladze, A., Simonia, G., Okrostsvardze, N., Kasradze, D., Revazishvili, P., et al. (2024). Chronotherapy Enhances Melatonin Secretion and Liver Enzyme Activity, Improving Therapeutic Outcomes in Hodgkin's Lymphoma Patients.
26. Simonia, G., Kasradze, D., Okrostsvardze, N., Revazishvili, P., Maisuradze, M., et al. (2024). Impact of Persistent Biochemical Alterations in Post-COVID Syndrome Patients on Cancer Risk, Cardiovascular Health, and Dyslipidemia A Comparative Study with Control Group. *Journal of Cancer Research*, 2(1), 1-22.
27. OpenAI. (2024). ChatGPT (Version GPT-4). Retrieved from <https://www.openai.com>.



**Professor Alexandre TAVARTKILADZE**



**Professor Gaiane Simonia**



**The Clinical and Genetic Laboratory  
Research Unit Head Dr. Rusudan  
Khutsishvili**



**Dr. Pati Revazishvili Head of Clinical Oncology  
Hematology and Internal Medicine Unit**



**Clinical Oncology Hematology Internal Medicine Unit**



**Professor Alexandre TAVARTKILADZE**